. GSK to Acquire Cancer PARP Inhibitor Developer TESAROBIO for $5.1B httpow.ly1QXI30mQr0dÂpic.twitter.compJMiIvrG5u
. @GSK to Acquire #Cancer PARP Inhibitor Developer @TESAROBIO for $5.1B: http://ow.ly/1QXI30mQr0d pic.twitter.com/pJMiIvrG5u
More From BioPortfolio on ". @GSK to Acquire #Cancer PARP Inhibitor Developer @TESAROBIO for $5.1B: http://ow.ly/1QXI30mQr0d pic.twitter.com/pJMiIvrG5u"